Skip to content
LexBuild

Oral Dosage Form New Animal Drugs; Ivermectin Paste

---
identifier: "/us/fr/E8-13607"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Oral Dosage Form New Animal Drugs; Ivermectin Paste"
title_number: 0
title_name: "Federal Register"
section_number: "E8-13607"
section_name: "Oral Dosage Form New Animal Drugs; Ivermectin Paste"
positive_law: false
currency: "2008-06-17"
last_updated: "2008-06-17"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "E8-13607"
document_type: "rule"
publication_date: "2008-06-17"
agencies:
  - "Health and Human Services Department"
  - "Food and Drug Administration"
cfr_references:
  - "21 CFR Part 520"
fr_citation: "73 FR 34184"
fr_volume: 73
effective_date: "2008-06-17"
fr_action: "Final rule."
---

#  Ivermectin paste.

**AGENCY:**

Food and Drug Administration, HHS.

**ACTION:**

Final rule.

**SUMMARY:**

The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental abbreviated new animal drug application (ANADA) filed by Cross Vetpharm Group Ltd. The supplemental ANADA adds effectiveness claims against various species of internal parasites when horses are treated with ivermectin paste.

**DATES:**

This rule is effective June 17, 2008.

**FOR FURTHER INFORMATION CONTACT:**

John K. Harshman, Center for Veterinary Medicine (HFV-104), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240-276-8197, e-mail: *[email protected]* .

**SUPPLEMENTARY INFORMATION:**

Cross Vetpharm Group Ltd., Broomhill Rd., Tallaght, Dublin 24, Ireland, filed a supplement to ANADA 200-326 for BIMECTIN (ivermectin) Paste 1.87% adding effectiveness claims against various species of internal parasites of horses. The supplemental ANADA is approved as of May 23, 2008, and 21 CFR 520.1192 is amended to reflect the approval.

In accordance with the freedom of information provisions of 21 CFR part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

The agency has determined under 21 CFR 25.33(a)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

**List of Subjects in 21 CFR Part 520**

Animal drugs.

**21 CFR Part 520**

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is amended as follows:

**21 CFR Part 520**

**PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS**

1. The authority citation for 21 CFR part 520 continues to read as follows:

**Authority:**

21 U.S.C. 360b.

**21 CFR Part 520**

2. In § 520.1192, remove paragraphs (b)(4) and (e)(1)(ii)(C) and revise paragraph (b)(3) to read as follows:

§ 520.1192

(b) * * *

(3) Nos. 051311, 054925, and 061623 for use of a 1.87 percent paste for use as in paragraphs (e)(1)(i), (e)(1)(ii)(A), and (e)(1)(iii) of this section.

Dated: June 9, 2008.

Bernadette Dunham,

Director, Center for Veterinary Medicine.